

Article

A Regioselective Iron-catalyzed [2+2+2] Cycloaddition Reaction Forming 4,6-Disubstituted-2-Aminopyridines from Terminal Alkynes and Cyanamides

Nathan A. Spahn, Minh H. Nguyen, Jonas Renner, Timothy K. Lane, and Janis Louie

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.6b02374 • Publication Date (Web): 17 Nov 2016

Downloaded from <http://pubs.acs.org> on November 18, 2016

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3 **A Regioselective Iron-catalyzed [2+2+2] Cycloaddition Reaction Forming 4,6-Disubstituted-2-**
4
5 **Aminopyridines from Terminal Alkynes and Cyanamides**
6
7

8 Nathan A. Spahn, Minh H. Nguyen, Jonas Renner, Timothy K. Lane, and Janis Louie*


9
10 Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, UT, 84112
11
12
13
14
15

16 **ABSTRACT:** Iron complexes bound by redox-active pyridine dialdimine (PDAI) ligands catalyze the cycloaddition
17 of two terminal alkynes and one cyanamide. The reaction is both chemo- and regioselective as only 4,6-
18 disubstituted-2-aminopyridine products are formed in moderate to high yields. Isolation of a Fe-azametallacycle (4)
19 suggests catalyst deactivation occurs with large excess of cyanamide over longer reaction times. Fe-catalyzed
20 cycloaddition allowed for a straightforward synthesis of a variety of amino-pyridines, including known estrogen
21 receptor ligands.
22
23
24
25
26
27
28
29
30
31

32 **Introduction.** Metal-catalyzed [2+2+2] cycloaddition reactions represent a powerful synthetic tool for the construction
33 of cyclic aromatic compounds in a single step.¹⁻⁶ Indeed, a variety of substituted aromatic compounds including
34 benzenes,⁷⁻⁸ pyridines,^{4-5,10-15} pyrimidines,¹⁶ and pyranones¹⁷⁻¹⁹ have been prepared through the use of transition metal
35 catalysts based on Ru,^{14,20-21} Rh,^{22,23} Co,²⁴⁻²⁸ Ir,²⁹⁻³¹ Mo,³² Ni,^{13,15,19} Ti,³³ Pd,³⁴⁻³⁶ and Fe.^{10-12,16,37-42} Of these metals, Co, Ni,
36 and Fe are particularly interesting because of their lower cost and wide availability. Despite the utility of this
37 transformation, almost all examples require the use of tethered pi-systems, typically in the form of a diyne, due to the
38 inherent difficulties in controlling both chemo- and regioselectivity. This is particularly true for synthetic strategies
39 that convert two alkynes and a nitrile into pyridine products as alkynes are inherently more reactive than nitrile
40 substrates.^{20,26,40-42} Furthermore, when terminal alkynes are coupled with a nitrile in a [2+2+2] cycloaddition, four
41 different pyridine regioisomers and two benzene isomers are possible, as well as other alkyne oligomers. For example,
42 Rh-catalyzed cycloaddition of two terminal alkynes and cyanamides, an activated nitrile, produced a 1.3:1 mixture of 4,6-
43 and 3,6-disubstituted 2-amino pyridines.²³ Similarly, equal amounts of 3,6- and 4,6-disubstituted-2-aminopyridine
44 products were formed in CoCp(CO)₂-catalyzed cycloadditions.²⁶ Some recent metal-free reports of regioselective
45 [2+2+2] cycloaddition reactions coupling cyanamides and nitriles or to yield the corresponding pyridines in high yields
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

have been reported.⁴³⁻⁴⁴ Nevertheless, the development of a more general chemo- and regioselective cycloaddition method for pyridine formation would represent a significant synthetic advance.

Our laboratory recently developed a Ni(COD)₂/SIPr (SIPr= 1,3-bis(2,6-diisopropylphenyl)imidazolidene) system that successfully catalyzes the cycloaddition reaction of terminal alkynes and cyanamides to provide the 3,5-disubstituted-2-aminopyridine regioisomer as the major product with reasonable regiocontrol.¹⁵ Additionally, two isolated reports of intermolecular Fe-catalyzed cycloaddition demonstrate chemo- and regioselective cycloadditions between alkynes and nitriles may be possible (eqs 1-2)^{11,12}. Interestingly, these two Fe-systems suggest regioselectivity may be controlled by choice of ligand. As such, we sought to define the generality of our chemo- and regioselective three-component methodology catalyzed by ^{Mes}PDAI-bound (^{Mes}PDAI=(1*E*,1'*E*)-1,1'-(pyridine-2,6-diyl)bis(*N*-mesitylmethanimine) Fe complexes. Herein, we report reaction conditions that afford 4,6-disubstituted-2-aminopyridine products regioselectively.



Results and Discussion. We initially focused on establishing a general cycloaddition protocol based on our Fe/PDAI system (eq 1) using alkyne **1a** and cyanamide **2a** as model substrates (Table 2). Many [2+2+2] cycloaddition reactions that couple two alkynes and a nitrile yield substituted benzenes as common side-products. Thus, we initially ran reactions with excess cyanamide **2a**. However, increasing the equivalence of cyanamide had no effect on the yield of pyridine product **3aa** or reduction in the amount of alkyne trimers formed.⁴⁵⁻⁴⁶ Instead, increased cyanamide equivalents led to the formation of complex **4**, an iron azametallacycle incorporating two cyanamides, over long reaction times. It is important to note that only trace amounts of complex **4** are obtained after the first hour. An

ORTEP diagram of complex **4** is shown in Figure 1 and selected bond lengths are shown in Table 1. Interestingly, complex **4** shares important ligand bond lengths with an (*i*Pr₃PDAI)Fe(DMAP) complex developed by Chirik and coworkers,⁴⁷ which suggests the complex possesses a radical dianionic ligand and an iron(IV) center. The geometry of complex **4** is distorted square pyramidal with the four iron-bound nitrogen atoms slightly out of the square plane with iron and the axial carbon offset toward the azametallacycle nitrogen. Complex **4** represents the only example of an isolated iron azametallacycle.




Figure 1. ORTEP diagram of (*i*Pr₃PDAI)Fe(NCNMe₂)₂ **4**


Table 1. Comparison of selected bond lengths for (*i*Pr₃PDAI)Fe(NCNMe₂)₂ and (*i*Pr₃PDAI)Fe(DMAP)⁴⁷

	(<i>i</i> Pr ₃ PDAI)Fe(NCNMe ₂) ₂	(<i>i</i> Pr ₃ PDAI)Fe(DMAP) ^a
N _{imine} - C _{imine}	1.334(2), 1.242(2)	1.339(3), 1.355(3)
C _{imine} - C _{ipso}	1.416(2), 1.407(3)	1.407(4), 1.406(4)
C _{ipso} - N _{py}	1.383(2), 1.389(2)	1.379(3), 1.373(3)
Fe _{cycle} - N _{cycle}	1.9684(15)	-
Fe _{cycle} - C _{cycle}	1.9956(17)	-

^aData taken from reference 47

When alkyne **1a** and cyanamide **2a** were subjected to catalytic amounts of complex **4**, only trace hexamethyl-1,3,5-triazine-2,4,6-triamine was observed along with unreacted starting materials (eq 3). As such, we believe complex **4**

is a catalyst sink, and large equivalents of cyanamide relative to Fe catalyst must be avoided to reduce formation of azametallacycle **4**.



In contrast, increasing the amount of alkyne relative to cyanamide successfully increased the yield of pyridine products. Three equivalents of alkyne led to greater consumption of cyanamide, while further equivalents of alkyne failed to increase the pyridine yields (eq 4). We also determined that zinc serves as a reductant for the iron halide pre-catalyst. That is, when **1a** and **2a** were combined with 5 mol% (^{Mes}PDAI)Fe(C₄H₆)⁴⁷ in the absence of zinc, **3aa** was obtained in an isolated yield of 80%. Nevertheless, we felt our optimized cycloaddition protocol with in situ formation of the Fe catalyst in the presence of zinc would be more practical and employed these conditions on a variety of alkynes and cyanamides (Table 2). The iron system is effective at coupling both aryl- and alkyl-substituted alkynes, which is a marked improvement over our Ni/IPr system that preferentially reacts with alkyl-substituted alkynes.¹⁵ The substitution pattern of the pyridine regioisomers were easily determined by 1D-NOESY NMR spectroscopy (see Supp Info). Yields in parentheses are adjusted relative to unreacted cyanamide. The unreacted cyanamide suggests that alkyne trimerization rates are comparable to the rate of cyclization between alkyne and cyanamide resulting in alkyne consumption prior to complete cyanamide conversion. Aryl alkynes reacted with dimethyl cyanamide **1a** to exclusively afford 4,6-aminopyridine products in high yields (Table 2, entries 1-6). Ortho-substitution (**1c**) on the aryl alkyne did not affect product yield. However, no conversion was observed when doubly ortho-substituted aryl alkynes such as 2,4,6-trimethylphenylacetylene was used as the cycloaddition partner. Both electron-donating and electron-withdrawing groups on the aryl ring were tolerated (entries 4-5) though slightly lower yields were obtained with electron-withdrawing substituents. Although low-valent Fe complexes are known to activate aryl halides,^{48,49} both 4-fluoro-1-

1
2
3 ethynylbenzene and 4-chloro-1-ethynylbenzene were amenable substrates (entries 5-6). Not surprisingly, high yields of
4
5 2-aminopyridine products were obtained when diethyl cyanamide **2b** and pyrrolidine-1-carbonitrile **2c** (entries 7-8).
6
7 Interestingly, lower yields were obtained when six-membered cyanamides, such as piperidine-1-carbonitrile **2d** and
8
9 morpholine-4-carbonitrile **2e**, were used as coupling partners. Cyanamides possessing easily removable groups, such as
10
11 allyl (**2f**) and benzyl (**2g**), were also successfully converted to pyridine products (entries 11-12). However, attempts at
12
13 using other protected cyanamides, such as *tert*-butylcarbamate and N-tosyl cyanamide, did not yield pyridine product,
14
15 which is likely due to less electron density at the nitrile nitrogen. In addition, when acetonitrile was used instead of
16
17 cyanamide, only alkyne oligomers were observed.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Iron catalyzed [2+2+2] cycloaddition of terminal alkynes and cyanamides^a

Entry	Alkyne	Cyanamide	Product	Yield(%) ^c	Entry	Alkyne	Cyanamide	Product	Yield (%) ^c
1 ^a	R=H, R'=H 1a	2a	R=H, R'=H 3aa	88 (93)	11 ^a	1a	R=allyl 2f	R=allyl 3af	32 (71)
2 ^a	R=Me, R'=H 1b	2a	R=Me, R'=H 3ba	82 (83)	12 ^a	1a	R=Bn 2g	R=Bn 3ag	78(82)
3 ^a	R=H, R'=Me 1c	2a	R=H, R'=Me 3ca	89					
4 ^a	R=OMe, R'=H 1d	2a	R=OMe, R'=H 3da	98					
5 ^a	R=F, R'=H 1e	2a	R=F, R'=H 3ea	69 (91)					
6 ^a	R=Cl, R'=H 1f	2a	R=Cl, R'=H 3fa	62 (82)					
7 ^a	1a			70 (>95)	13 ^b	R=CH ₂ CH ₃ 1g	2a	R=CH ₂ CH ₃ 3ga	55 (92)
8 ^a	1a			86 (87)	14 ^b	R=OTBS 1h	2a	R=OTBS 3ha	83 (89)
9 ^a	1a		R=CH ₂ 3ad	44 (83)	15 ^b	R=CH ₂ OTBS 1i	2a	R=CH ₂ OTBS 3ia	69 (>95)
10 ^a	1a		R=O 3ae	48 (>95)	16 ^c	R=CH ₂ Ph 1j	2a	R=CH ₂ Ph 3ja	59 (>95)
					17 ^b		2a		60 (89)
					18 ^b		2a		54 (76)
					19 ^b		2a		69 (>95)

^a5 mol % FeI₂, 10 mol % MesPDAI, 10 mol % Zn, 3 equiv. alkyne, 0.4 M cyanamid, toluene, rt


^b5 mol % FeI₂, 10 mol % MesPDAI, 10 mol % Zn, 3 equiv alkyne added dropwise over 3 hours, 0.4 M cyanamide, toluene, rt

^cisolated yields, brsm yields in parenthesis

Unlike our Ni system which preferentially converted alkyl alkynes over aryl alkynes, the Fe/PDAI combination effectively catalyzes the cycloaddition of both aryl alkynes and alkyl alkynes. For alkyl alkynes, slow addition of the alkyne over the course of three hours ensured pyridine product formation over cyclotrimerization of alkyl alkynes. Catalyst deactivation through complex **4** does not occur because it does not appreciably form at shorter reactions times. Oxygen functional groups, such as protected alcohols **1h** and **1i**, as well as alkynes possessing a distal aromatic group (**1j**) were successfully employed in the cycloaddition reaction to yield the corresponding 2-amino pyridines in good yields (entries 14-16). Pyridine products were also formed from the use of trimethylsilyl protected acetylene (entry 17)

and ethynylcyclopropane (entry 18). The use of propargyl chloride as a coupling partner shut down the cycloaddition, which is likely due to irreversible oxidation of the Fe catalyst. Adding substitution to the 3 position of the terminal alkynes and when using methyl propiolate afforded only alkyne oligomers, despite slow addition of alkyne. To our surprise, sulfur-containing 3-ethynylthiophene **1m** was also converted to pyridine product, despite iron's propensity to bind sulfur compounds (entry 19).⁵⁰

4,6-Diaryl-2-aminopyridine pyridines are known estrogen receptor ligands for both the alpha and beta receptor proteins (ER α and ER β).⁵¹ We believed that we could apply our Fe-catalyzed cycloaddition methodology to construct the pyridine core of one of these compounds in a single step. Thus, we subjected *tert*-butyl(4-ethynylphenoxy)dimethylsilane and *N*-methyl-*N*-phenethylcyanamide to the standard cycloaddition conditions, and, gratifyingly, the corresponding protected estrogen receptor was isolated in 76% yield (Scheme 1). After deprotection with KOH, the estrogen receptor ligand was isolated in 70% overall yield over two steps. This Fe-catalyzed cycloaddition protocol is a marked improvement over the previous synthetic pathway which is a four step process with an overall yield of 35%.⁵¹



Scheme 1. Fe-catalyzed cycloaddition approach to an estrogen receptor ligand

In conclusion, we have presented a general [2+2+2] cycloaddition that exhibits unprecedented exclusive selectivity for the 4,6-disubstituted-2-aminopyridines. The reaction is synthetically practical and tolerant of both aryl and alkyl substituted alkynes as well as a variety of functional groups. Additional experiments are being conducted to determine selectivity for mixed pyridine products when two different terminal alkynes are employed. In addition, the regioselective Fe-catalyzed cycloaddition protocol was used to prepare known estrogen substitutes and ligands for the

ER α and ER β proteins. The mechanism of this catalyst system and the origin of the regioselectivity are currently being explored by our laboratory.

Experimental Section

General Experimental: All reactions were conducted in a N₂ filled glove-box unless otherwise noted. Toluene was dried over neutral alumina under N₂ using a Grubbs type solvent purification system. FeI₂ was purchased from Sigma-Aldrich and used without further purification. MesPDAI was synthesized via literature methods. All alkynes and cyanamides were purchased from commercial sources. Liquid cyanamides and alkynes were degassed using three sequential freeze-pump thaw cycles. ¹H and ¹³C Nuclear Magnetic Resonance spectra of pure compounds were acquired at 400 and 101 MHz respectively, unless otherwise noted. All spectra are referenced to a singlet at 7.26 ppm for ¹H and to the center line of a triplet at 77.0 ppm for ¹³C. The abbreviations s, d, dd, dt, dq, t, q, and quint stand for singlet, doublet, doublet of doublets, doublet of triplets, doublet of quartets, triplet, quartet, and quintet, respectively. All ¹³C NMR spectra were proton decoupled. Preparatory TLC was performed on Silica Gel TLC plates 60 F256 from Merk KGaA. IR spectra were obtained using a Bruker Tensor 27 spectrometer on KBr discs. Calculated HRMS data was obtained from ChemDraw software.


Method A. In a nitrogen-filled glovebox, 2 mL vial was charged with iron iodide (0.05 equiv.) and MesPDAI ((1E,1'E)-1,1'-(pyridine-2,6-diyl)bis(N-mesitylmethanimine)) (0.10 equiv.) and toluene to bring the final molarity to 0.4 M. The catalyst solution was stirred for 20 minutes at which time cyanamide (1 equiv.) was added. The reaction was stirred for 5 minutes before zinc (0.1 equiv.) was added. The reaction was stirred for another 5 minutes and alkyne (3 equiv.) was added. The reaction was stirred overnight and the crude reaction mixture passed through a Celite plug. The product was isolated by preparatory TLC.

Method B. In a nitrogen-filled glovebox, 2 mL vial was charged with iron iodide (0.05 equiv.) and MesPDAI ((1E,1'E)-1,1'-(pyridine-2,6-diyl)bis(N-mesitylmethanimine)) (0.10 equiv.) and toluene to bring the final molarity to 0.4 M. The catalyst solution was stirred for 20 minutes at which time cyanamide (1 equiv.) was added. The reaction was stirred for 5 minutes before zinc (0.1 equiv.) was added. The reaction was stirred for another 5 minutes and alkyne (3 equiv.) was added by syringe pump over 3 hours. The reaction was stirred overnight and the crude reaction mixture passed through a Celite plug. The product was isolated by preparatory TLC.

Synthesis of Complex 4. In a nitrogen-filled glovebox, a vial was charged with (ⁱPrPDAI)FeBr₂ (1 equiv., 100 mg, 0.15 mmol) and 0.25 mL of toluene and a stir bar was added to the vial. Cyanamide **1a** (10 equiv., 121 μ L, 1.5 mmol) was added to the vial and the resulting reaction was stirred for 30 minutes. Sodium mercury amalgam or zinc (2.5 equiv.)


was added to the vial and the reaction was allowed to stir overnight. The resulting solution was passed through Celite and residual reactant in the reaction vial was dissolved with THF and also passed through Celite. All solvents were removed in vacuo. Pentane was added to the residue and the heterogeneous solution was again passed through Celite. Pentane was allowed to slowly evaporate at room temperature to give green crystals of **Complex 4**.

Synthesis of N,N-dimethyl-4,6-diphenylpyridin-2-amine (**3aa**)




Method A for the cycloaddition was used with iron iodide (2.8 mg, 0.0091 mmol), ^{Mes}PDAI (6.7 mg, 0.0182 mmol), alkyne **1a** (60 μL, 0.546 mmol), and cyanamide **2a** (14.8 μL, 0.182 mmol). The product was isolated by preparatory TLC (10% ethyl acetate in hexanes, R_f = 0.6) in 88% (43.9 mg) yield of pyridine **3aa** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, J = 7.5 Hz, 2H), 7.70 (d, J = 7.3 Hz, 2H), 7.52 – 7.39 (m, 6H), 7.29 (s, 1H), 6.68 (s, 1H), 3.25 (s, 6H). ¹³C (75 MHz, CDCl₃) δ 159.6, 155.5, 150.6, 140.3, 140.2, 128.8, 128.5, 128.4, 127.1, 126.9 (2C), 107.2, 102.5, 38.1. IR (cm⁻¹) 3059, 3035, 2925, 2853, 1598, 1547, 1499, 1250, 1183. HRMS (ESI) *m/z* calcd for C₁₉H₁₈N₂ [M+H]⁺ 275.1543, found 275.1541.

1D NOESY Relationships




Synthesis of N,N-dimethyl-4,6-di-p-tolylpyridin-2-amine (**3ba**)¹¹




Method A for the cycloaddition reaction was used with iron iodide (2.5 mg, 0.00825 mmol), ^{Mes}PDAI (6.1 mg, 0.0165 mmol) alkyne **1b** (62.8 μL, 0.495 mmol), and cyanamide **2a** (13.4 μL, 0.165 mmol). The crude product was purified by preparatory TLC (10% ethyl acetate in hexanes, R_f = 0.6) in 82% (41.0 mg) yield of pyridine **3ba** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, J = 7.8 Hz, 2H), 7.57 (d, J = 7.7 Hz, 2H), 7.25–7.23 (m, 5H), 6.61 (s, 1H), 3.20 (s, 6H), 2.41 (s, 3H), 2.40 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 159.6, 155.5, 138.3, 237.5, 137.4, 129.5, 129.1, 126.9, 126.7, 106.8, 101.9, 38.1, 21.3, 21.2. IR (cm⁻¹) 3027, 2922, 2858, 2803, 1600, 1545, 1512, 1417, 1401, 1182. HRMS (ESI) *m/z* calcd for C₂₁H₂₃N₂ [M+H]⁺ 303.1856, found 303.1863.

1D NOESY relationships:




Synthesis of N,N-dimethyl-4,6-di-o-tolylpyridin-2-amine (3ca)




Method A for the cycloaddition was used with iron iodide (2.5 mg, 0.00825 mmol), ^{Mes}PDAI (6.1 mg, 0.0165 mmol), alkyne **1c** (62.4 μL, 0.495 mmol), and cyanamide **2a** (13.4 μL, 0.165 mmol). The crude product was purified by preparatory TLC (10% ethyl acetate in hexanes, R_f = 0.6) in 89% (44.5) yield of pyridine **3ca** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.53 (dd, J = 5.3, 1.8 Hz, 1H) 7.47-7.22 (m, 7H), 6.70 (s, 1H), 6.44 (s, 1H), 3.18 (s, 6H), 2.54 (s, 3H), 2.37 (s, 3H). ¹³C (75 MHz, CDCl₃) δ 158.8, 157.7, 151.1, 141.2, 140.9, 136.1, 135.1, 130.7, 130.4, 129.7, 129.1, 127.74, 127.71, 125.8, 125.6, 113.1, 104.0, 38.1, 20.9, 20.4. IR (cm⁻¹) 3060, 3019, 2924, 2855, 1595, 1574, 1547, 1497, 1401, 1379, 1122. HRMS (ESI) *m/z* calcd for C₂₁H₂₂N₂ [M+H]⁺ 303.1856, found 303.1861.

1D NOESY Relationships




Synthesis of 4,6-bis(4-methoxyphenyl)-N,N-dimethylpyridin-2-amine (3da)




Method A for the cycloaddition reaction was used with iron iodide (2.3 mg, 0.0075 mmol), ^{Mes}PDAI (5.5 mg, 0.015 mmol), alkyne **1d** (58.4 μL, 0.450 mmol), cyanamide **2a** (12.2 μL, 0.150 mmol). The product was isolated by preparatory TLC (10% ethyl acetate and hexanes, R_f = 0.6) in 98% (49.0 mg) yield of pyridine **3da** as a yellow solid. mp 122-125 °C; ¹H NMR (400

MHz, CDCl₃) δ 8.07 (d, J = 8.8 Hz, 2H), 7.67-7.60 (m, 2H), 7.19 (s, 1H), 7.05-6.96 (m, 4H), 6.59 (s, 1H), 3.97 (s, 6H), 3.22 (s, 6H). ¹³C (101 MHz, CDCl₃) δ 160.1, 160.0, 159.6, 155.2, 150.1, 133.0, 132.8, 128.2, 128.1, 114.2, 113.7, 106.2, 101.3, 55.34, 55.29, 38.1. IR (cm⁻¹) 3027, 2922, 2855, 1601, 1546, 1513, 1417, 1400, 1183. HRMS (ESI) *m/z* calcd for C₂₁H₂₂N₂O₂ [M+H]⁺ 335.1754, found 335.1758.

1D NOESY Relationships



Synthesis of 4,6-bis(4-fluorophenyl)-N,N-dimethylpyridin-2-amine (3ea)¹²




Method A for the cycloaddition reaction was used with iron iodide (2.5 mg, 0.00805 mmol), Mes²PDAI (5.9 mg, 0.0161 mmol), alkyne **1e** (55.4 μL, 0.483 mmol), and cyanamide **2a** (13.1 μL, 0.161 mmol). The crude product was purified by preparatory TLC (10 % ethyl acetate in

hexanes, R_f = 0.5) in 69% (34.5 mg) yield of pyridine **3ea** as a white solid. mp 128-129 °C; ¹H


NMR (400 MHz, CDCl₃) δ 8.16-8.03 (m, 2H), 7.73-7.58 (m, 2H), 7.24-7.07 (m, 5H), 6.58 (s, 1H),

3.22 (s, 6H). ¹³C (75 MHz, CDCl₃) δ 163.3 (J_{C-F} = 246.0 Hz), 163.1 (J_{C-F} = 246.0 Hz), 159.5, 154.6, 149.7, 136.3 (J_{C-F} = 3.3 Hz), 136.2 (J_{C-F} = 3.0 Hz), 128.8 (J_{C-F} = 8.2 Hz), 128.6 (J_{C-F} = 8.2 Hz), 115.7 (J_{C-F} = 21.5 Hz), 115.3 (J_{C-F} = 21.5 Hz), 106.6, 102.2, 38.1. IR (cm⁻¹) 3068, 2926, 2854, 1607, 1550, 1508, 1399, 1294, 1185, 1156. HRMS (ESI) *m/z* calcd for C₁₉H₁₆F₂N₂ [M+H]⁺ 311.1354, found 311.1358.

1D NOESY Relationships




Synthesis of 4,6-bis(4-chlorophenyl)-N,N-dimethylpyridin-2-amine (**3fa**)




Method A for the cycloaddition reaction was used with iron iodide (2.3 mg, 0.0073 mg), ^{Mes}PDAI (5.4 mg, 0.0146 mmol), alkyne **1f** (59.8 mg, 0.438 mmol), and cyanamide **2a** (11.9 μL, 0.146 mmol). The crude product was purified by preparatory TLC (10% ethyl acetate in hexanes, R_f = 0.4) in 62% (31.0 mg) yield of pyridine **3fa** as a white solid. mp 157-160 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, J = 8.5 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H), 7.45-7.50 (m, 4H), 7.15 (s, 1H), 6.59 (s, 1H), 3.22 (s, 6H). ¹³C (75 MHz, CDCl₃) δ 159.5, 154.5, 149.5, 138.5, 138.4, 134.6, 134.5, 129.0, 128.6, 128.4, 128.1, 106.6, 102.4, 38.1. IR (cm⁻¹) 2924, 2852, 1603, 1546, 1490, 1417, 1396. HRMS (ESI) *m/z* calcd for C₁₆H₁₆Cl₂N₂ [M+H]⁺ 343.0763, found 343.0771.

¹D NOESY Relationships




Synthesis of N,N-diethyl-4,6-diphenylpyridin-2-amine (**3ab**)⁵²




Method A for the cycloaddition was used with iron iodide (2.8 mg, 0.0090 mmol), ^{Mes}PDAI (6.7 mg, 0.0180 mmol), alkyne **1a** (59.3 μL, 0.540 mmol), and cyanamide **2b** (20.9 μL, 0.180 mmol). The product was isolated by preparatory TLC (5% ethyl acetate in hexanes, R_f = 0.6) in 70% (35.0 mg) yield of pyridine **3ab** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.15-8.07 (m, 2H), 7.71-7.64 (m, 2H), 7.52-7.40 (m, 6H), 7.22 (s, 1H), 6.60 (s, 1H), 3.68 (q, J = 7.0 Hz, 4H), 1.29 (t, J = 7.0 Hz, 6H). ¹³C (101 MHz, CDCl₃) δ 157.7, 155.7, 150.6, 140.6, 140.4, 131.3, 128.8, 128.4, 128.3, 127.1, 126.8, 106.7, 102.2, 42.7, 13.2. IR (cm⁻¹) 2959, 2923, 2852, 1596, 1511, 1482, 1452, 1440, 1287. HRMS (ESI) *m/z* calcd for C₂₁H₂₂N₂ [M+H]⁺ 303.1856, found 303.1857.

¹D NOESY Relationships



Synthesis of 2,4-diphenyl-6-(pyrrolidin-1-yl)pyridine (**3ac**)⁵²




Method A for the cycloaddition was used with iron iodide (2.6 mg, 0.00825 mmol), ^{Mes}PDAI (7.0 mg, 0.0165 mmol), alkyne **1a** (54.3 μ L, 0.495 mmol), and cyanamide **2c** (16.6 μ L, 0.165 mmol).


The product was isolated by preparatory TLC (10% ethyl acetate in hexanes) in 87% (43.5 mg) yield of pyridine **3ac** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.15-8.06 (m, 2H), 7.72-7.64

(m, 2H), 7.54-7.33 (m, 6H) 7.24 (d, J = 1.0 Hz, 1H), 6.51 (s, 1H), 3.63 (t, J = 6.5 Hz, 4H), 2.06 (t, J = 6.5 Hz, 4H). ¹³C (101 MHz, CDCl₃) δ 157.7, 155.9, 150.3, 140.3 (2C), 128.8, 128.41, 128.39, 128.36, 127.1, 126.9, 106.9, 103.0, 46.8, 25.6. IR (cm⁻¹) 3060, 2925, 2855, 1605, 1542, 1453, 1385, 1271. HRMS (ESI) *m/z* calcd for C₂₁H₂₀N₂ [M+H]⁺ 301.1699, found 301.1698.

¹D NOESY Relationships



Synthesis of 2,4-diphenyl-6-(piperidin-1-yl)pyridine (**3ad**)⁵²





Method A for the cycloaddition was used with iron iodide (3.4 mg, 0.0079 mmol), ^{Mes}PDAI (5.8 mg, 0.0159 mmol), alkyne **1a** (52.3 μ L, 0.477 mmol), and cyanamide **2d** (18.4 μ L, 0.159 mmol).

The product was isolated by preparatory TLC (5% ethyl acetate in hexanes, R_f = 0.6) in 83% (41.5 mg) yield of pyridine **3ad** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.09 (dt, J = 8.3, 1.8 Hz,

2H), 7.71-7.62 (m, 2H), 7.53-7.34 (m, 6H), 7.37 (s, 1H), 6.80 (s, 1H) 3.71 (t, J = 5.6 Hz, 4H), 1.74-1.68 (m, 6H). ¹³C (101 MHz, CDCl₃) δ 159.9, 155.7, 140.3, 140.2, 128.8, 128.5, 128.4, 127.1, 126.9 (2C), 108.1, 103.8, 46.4, 25.6, 24.9. IR (cm⁻¹) 3060, 2931, 2852, 1595, 1545, 1495, 1447, 1243. HRMS (ESI) calcd for C₂₂H₂₂N₂ [M+H]⁺ 315.1856, found 315.1856.

1D NOESY Relationships



Synthesis of 4-(4,6-diphenylpyridin-2-yl)morpholine (**3ae**)⁵²

Method A for the cycloaddition was used with iron iodide (2.4 mg, 0.0079 mmol), ^{Mes}PDAI (5.8 mg, 0.0158 mmol), alkyne **1a** (52.0 μL, 0.474 mmol) and cyanamide **2e** (16.0 μL, 0.158 mmol).

The product was isolated by preparatory TLC (10% ethyl acetate in hexanes, R_f = 0.3) in 48%

(24.0 mg) yield of pyridine **3ae** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, J = 7.4 Hz, 2H), 7.66 (d, J = 7.2 Hz, 2H), 7.54-7.35 (m, 7H), 3.90 (t, J = 4.0 Hz, 4H) 3.69 (t, J = 4.0 Hz, 4H). ¹³C (101 MHz, CDCl₃) δ 159.8, 155.8, 151.2, 139.9, 139.8, 128.9, 128.7, 128.6, 128.5, 127.1, 126.9, 109.4, 103.6, 66.9, 45.8. IR (cm⁻¹) 3061, 2961, 2921, 2852, 1595, 1546, 1497, 1447, 1425, 1238. HRMS (ESI) *m/z* calcd for C₂₁H₂₀N₂O [M+H]⁺ 317.1648, found 317.1649.

1D NOESY Relationships

Synthesis of N,N-diallyl-4,6-diphenylpyridin-2-amine (**3af**)


Method A for the cycloaddition was used with iron iodide (2.8 mg, 0.0090 mmol), ^{Mes}PDAI (6.7 mg, 0.0180 mmol), alkyne **1a** (59.3 μL, 0.540 mmol), and cyanamide **2f** (24.4 μL, 0.180 mmol).

The product was isolated by preparatory TLC (5% ethyl acetate in hexanes, R_f = 0.6) in 32%

(16.0 mg) yield of pyridine **3af** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.10 (dd, J = 5.3, 3.3 Hz, 2H), 7.68-7.1 (m, 2H), 7.52-7.34 (m, 8H), 7.28 (d, J = 1.0 Hz, 1H) 6.62 (d, J = 1.0 Hz, 1H), 5.97 (ddt, J = 17.1, 10.4, 5.3 Hz, 2H), 5.33-5.15 (m, 4H), 4.28 (d, 4.3 Hz, 4H). ¹³C (101 MHz, CDCl₂) δ 158.2, 155.5, 150.7, 140.3,


1
2
3 140.1, 134.4, 128.8, 128.5, 128.4, 127.1, 126.8 (2C), 116.2, 107.5, 102.9, 50.4. IR (cm⁻¹) 3061, 3034, 2979, 2922, 2853, 1596, 1546,
4
5 1480, 1223. HRMS (ESI) *m/z* calcd for C₂₃H₂₂N₂ [M+H]⁺ 327.1856, found 327.1851.
6
7

8 1D NOESY Relationships




20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Synthesis of N,N-dibenzyl-4,6-diphenylpyridin-2-amine (3ag)




Method A for the cycloaddition was used with iron iodide (2.8 mg, 0.0090 mmol), ^{Mes}PDAI (6.7 mg, 0.0180 mmol), alkyne **1a** (59.3 μL, 0.540 mmol), and cyanamide **2g** (40 mg, 0.180 mmol). The product was isolated by preparatory TLC (10% ethyl acetate in hexanes, R_f = 0.6) in 78% (39.0 mg) yield of pyridine **3ag** as a yellow-green solid. mp 106-108 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.17-8.09 (m, 2H), 7.61-7.54 (m, 2H), 7.49-7.36 (m, 15H), 7.34-7.28 (m, 2H), 6.68 (s, 1H), 4.99 (s, 4H). ¹³C (101 MHz, CDCl₃) δ 158.8, 155.5, 151.0, 140.0, 139.9, 138.8, 128.8, 128.6, 128.4, 128.2, 128.1, 127.3, 127.1, 126.9, 126.8, 107.9, 102.6, 51.1. IR (cm⁻¹) 3084, 3061, 3030, 2919, 2855, 1596, 1547, 1496, 1480, 1450, 1361, 1221. HRMS (ESI) *m/z* calcd for C₃₁H₂₆N₂[M+H]⁺ 427.2169, found 427.2171.

1D NOESY Relationships



Synthesis of N,N-dimethyl-4,6-dipropylpyridin-2-amine (3ga)¹⁵




Method B for the cycloaddition reaction was used with iron iodide (3.7 mg, 0.0121 mmol), ^{Mes}PDAI (9 mg, 0.0242 mmol), alkyne **1g** (49.5 mg, 0.726 mmol), and cyanamide **2a** (17.0 mg, 0.242 mmol).


The crude product was isolated by preparatory TLC (5% ethyl acetate in hexanes, R_f = 0.4) in 55% (27.5 mg) yield of pyridine **3ga** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 6.26 (s, 1H), 6.15 (s,

1H), 3.06 (s, 6H), 2.58 (t, J = 8 Hz, 2H), 2.46 (t, J = 8 Hz, 2H), 1.81-1.55 (m, 4H), 1.0-0.90 (m, 6H). ¹³C (101 MHz, CDCl₃) δ 160.1, 159.5, 152.5, 111.2, 102.6, 40.4, 38.0, 37.9, 23.7, 22.6, 14.0, 13.9. IR (cm⁻¹) 2959, 2930, 2871, 1604, 1564, 1498, 1420, 1185. HRMS (ESI) *m/z* calcd for C₁₃H₂₂N₂ [M+H]⁺ 207.1856, found 207.1862.

1D NOESY Relationships



Synthesis of 4,6-bis(((tert-butyldimethylsilyl)oxy)methyl)-N,N-dimethylpyridin-2-amine (**3ha**)¹⁵




Method B for the cycloaddition reaction was used with iron iodide (2.8 mg, 0.00915 mmol), ^{Mes}PDAI (6.8 mg, 0.083 mmol), alkyne **1h** (111.3 μL, 0.459 mmol), and cyanamide **2a** (14.9 μL,


0.183 mmol). The crude product was purified by preparatory TLC (10% ethyl acetate in hexanes,

R_f = 0.6) in 83% (62.3 mg) yield of pyridine **3ha** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 6.69 (s, 1H), 6.43 (s, 1H), 4.68 (s, 4H), 3.07 (s, 6H), 0.96 (s, 9H), 0.97 (s, 9H), 0.12 (s, 6H), 0.11 (s, 6H). ¹³C (101 MHz, CDCl₃) δ 159.1, 159.0, 104.9, 100.7, 66.3, 64.3, 38.1, 26.0, 25.9, 18.43, 18.37, -5.31 (2C). IR (cm⁻¹) 2955, 2929, 2857, 1610, 1569, 1501, 1471, 1421, 1391, 1255, 1147, 1107. HRMS (ESI) *m/z* calcd for C₂₁H₄₂N₂O₂Si₂ [M+H]⁺ 411.2858, found 411.2864.

1D NOESY Relationships




Synthesis of 4,6-bis-((tert-butyl dimethylsilyl)oxy)ethyl)-N,N-dimethylpyridin-2-amine (**3ia**)¹⁵




Method B for the cycloaddition reaction was used with iron iodide (2.6 mg, 0.00855 mmol), ^{Mes}PDAI (6.3 mg, 0.0171 mmol), alkyne **ii** (105.9 μ L, 0.513 mmol), and cyanamide **2a** (13.9 μ L, 0.171 mmol). The crude product was purified by preparatory TLC (10 % Ethyl acetate in hexanes, R_f = 0.6) in 69% (51.8 mg) yield of pyridine **3ia** as a yellow oil. ¹H NMR (300 MHz, CDCl₃) δ 6.32 (s, 1H), 6.20 (s, 1H), 3.96 (t, J = 7.1 Hz, 2H), 3.78 (t, J = 7.0 Hz, 2H), 3.05 (s, 6H), 2.82 (t, J = 7.1 Hz, 2H), 2.69 (t, J = 7.0 Hz, 2H), 0.88 (s, 9H), 0.87 (s, 9H), 0.01 (s, 6H), 0.00 (s, 6H). ¹³C (101 MHz, CDCl₃) δ 159.4, 156.9, 149.1, 112.6, 103.8, 63.7, 63.2, 41.8, 39.4, 38.0, 26.0, 25.9, 18.33, 18.29, -5.33, -5.37. IR (cm⁻¹) 2955, 2930, 2886, 2858, 1607, 1564, 1472, 1421, 1389, 1255, 1099. HRMS (ESI) m/z calcd for C₂₃H₄₆N₂O₂Si₂ [M+H]⁺ 439.3171, found 439.3175.

¹D NOESY Relationships




Synthesis of N,N-dimethyl-4,6-diphenethylpyridin-2-amine (**3ja**)¹⁵




Method B was for the cycloaddition was used with iron iodide (2.3 mg, 0.0076 mmol), ^{Mes}PDAI (5.6 mg, 0.0151 mmol), alkyne **ij** (63.7 μ L, 0.453 mmol), and cyanamide **2a** (12.3 μ L, 0.151 mmol). The crude product was purified by preparatory TLC (10 % ethyl acetate in hexanes, R_f = 0.6) in 59% (29.5 mg) yield of pyridine **3ja** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.35-7.2 (m, 10H), 6.29 (s, 1H), 6.16 (s, 1H), 3.10-3.07 (m, 8H), 2.89-2.98 (m, 4H), 2.81 (dd, J = 10.0, 6.2 Hz, 2H). ¹³C (101 MHz, CDCl₃) δ 159.5, 159.2, 151.7, 142.5, 141.5, 128.5, 128.4, 128.3, 128.2, 125.9, 125.6, 111.1, 102.9, 40.0, 38.0, 37.7, 36.9, 35.5. IR (cm⁻¹) 3084, 3062, 3026, 2924, 2857, 1603, 1563, 1496, 1454, 140, 1192. HRMS (ESI) m/z calcd for C₂₃H₂₆N₂ [M+H]⁺ 331.2169, found 331.2174.

¹D NOESY Relationships




Synthesis of N,N-dimethyl-4,6-bis(trimethylsilyl)pyridin-2-amine (**3ka**)




Method B for the cycloaddition was used with iron iodide (2.9 mg, 0.0094 mmol), ^{Mes}PDAI (6.9 mg, 0.0188 mmol), alkyne **1k** (79.7 μ L, 0.564 mmol), and cyanamide **2a** (15.3 μ L, 0.188 mmol). The crude product was purified by preparatory TLC (10% ethyl acetate in hexanes, R_f = 0.5) in 60% (30.0 mg) yield of pyridine **3ka** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 6.88 (s, 1H), 6.57 (s, 1H), 3.11 (s, 6H), 0.29 (s, 9H), 0.27 (s, 9H). ¹³C (101 MHz, CDCl₃) δ 164.1, 157.9, 148.0, 121.0, 109.5, 37.8, -1.5, -1.7. IR (cm⁻¹) 2956, 2898, 2855, 2802, 1574, 1520, 1486, 1396, 1334, 1248, 1184. HRMS (ESI) m/z calcd for C₁₃H₂₆N₂Si₂ [M+H]⁺ 267.1707, found 267.1712.

¹D NOESY Relationships




Synthesis of 4,6-dicyclopropyl-N,N-dimethylpyridin-2-amine (**3la**)¹⁵




Method B for the cycloaddition was used with iron iodide (3.9 mg, 0.0124 mmol), ^{Mes}PDAI (9.1 mg, 0.0247 mmol), alkyne **1l** (62.7 μ L, 0.741 mmol), and cyanamide **2a** (20.1 μ L, 0.247 mmol). The crude product was purified by preparatory TLC (10% ethyl acetate in hexanes, R_f = 0.6) in 54% (27.0 mg) yield of pyridine **3la** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 6.13 (s, 1H), 6.02 (s, 1H), 3.01 (s, 6H), 1.88-1.79 (m, 1H), 1.79-1.71 (m, 1H), 1.04-0.91 (m, 4H), 0.85-0.78 (m, 2H), 0.78-0.72 (m, 2H). ¹³C (101 MHz, CDCl₃) δ 160.3, 159.4, 154.2, 106.3, 99.6, 37.8, 16.9, 15.3, 9.3, 8.7. IR (cm⁻¹) 3085, 3005, 2927, 2856, 2801, 1603, 1561, 1498, 1422, 1400, 1177. HRMS (ESI) m/z calcd for C₁₃H₁₈N₂ [M+H]⁺ 203.1543, found 203.1551.

¹D NOESY Relationships




Synthesis of N,N-dimethyl-4,6-di(thiophen-3-yl)pyridin-2-amine (3ma)




Method B for the cycloaddition was used with iron iodide (2.7 mg, 0.00875 mmol), ^{Mes}PDAI (6.5 mg, 0.0175 mmol), alkyne **1m** (51.7 μ L, 0.525 mmol), and cyanamide **2a** (14.2 μ L, 0.175 mmol). The product was isolated by preparatory TLC (10% ethyl acetate in hexanes, R_f = 0.5) in 69% (34.5 mg) yield of pyridine **3ma** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.93 (dd, J = 3.0, 0.9 Hz, 1H), 7.71 (dd, J = 5.0, 0.8 Hz, 1H), 7.71 (dd, J = 5.0, 0.8 Hz, 1H), 7.62 (dd, J = 2.8, 1.2 Hz, 1H) 7.50-7.33 (m, 3H), 7.13 (s, 1H), 6.61 (s, 1H), 3.20 (s, 6H). ¹³C (101 MHz, CDCl₃) δ 159.6, 151.9, 144.7, 143.2, 141.3, 126.40, 126.35, 126.2, 125.6, 122.9, 122.1, 106.4, 101.3, 38.0. IR (cm⁻¹) 3102, 2924, 2852, 2801, 1603, 1554, 1526, 1418, 1186, 1173. HRMS (ESI) m/z calcd for C₁₅H₁₄N₂S₂ [M+H]⁺ 287.0671, found 287.0677.

1D NOESY Relationships



Synthesis of 4,6-bis(4-((tert-butyl)dimethylsilyloxy)phenyl)-N-methyl-N-phenethylpyridin-2-amine (3nh)




Method A for the cycloaddition was used with iron iodide (1.2 mg, 0.0040 mmol), ^{Mes}PDAI (3.0 mg, 0.008 mmol), tert-butyl(4-ethynylphenoxy)dimethylsilane (55.8 mg, 0.240 mmol), and N-methyl-N-phenethylcyanamide (12.8 mg, 0.08 mmol). The product was isolated by preparatory TLC (10% ethyl acetate in hexanes, R_f = 0.5) in 76% (38 mg) yield of pyridine **3nh** as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, J = 8.5 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.27-7.10 (m, 6H), 6.88-6.83 (m, 4H), 6.45 (s, 1H), 3.84 (t, J = 7.5 Hz, 2H), 3.03 (s, 3H), 2.92 (t, J = 7.5 Hz, 2H), 0.95 (s, 18H), 0.18-0.17 (m, 12H). ¹³C (75 MHz, CDCl₃) δ 158.4, 156.3, 156.2, 155.2, 150.2,


1
2
3 140.2, 133.6, 133.4, 128.9, 128.4, 128.1, 128.0, 126.1, 120.3, 120.0, 106.2, 101.2, 52.6, 36.9, 33.8, 29.7, 25.72, 25.69, 18.3, 4.4 (2C).

4
5 IR (cm⁻¹) 2955, 2929, 2857, 1604, 1545, 1510, 1264, 1168. HRMS (ESI) *m/z* calcd for C₃₈H₅₂N₂O₂Si₂ [M+H]⁺ 625.3640, found
6
7 625.3646.

8
9
10 **1D NOESY Relationships**



23
24 **Synthesis of 4,4'-(6-(methyl(phenethyl)amino)pyridine-2,4-diyl)diphenol (5)⁵¹**



A 2 mL vial was charged with 4,6-bis(4-((tert-butyldimethylsilyl)oxy)phenyl)-N-methyl-N-phenethylpyridin-2-amine (39 mg, 0.03 mmol), potassium hydroxide (10.6 mg, 0.189 mmol), and ethanol (0.5 mL) with a magnetic stir bar. The reaction was monitored stirred for 4 hours and filtered through Celite. Solvent was removed in vacuo and the crude product was purified by preparatory TLC (50% ethyl acetate in hexanes, R_f = 0.5) to give

35 92% (35.9 mg) yield of deprotected pyridine 5 as a green oil. ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, J = 8.5 Hz, 2H), 7.66 (d, J = 8.5 Hz, 2H), 7.45-7.30 (m, 6H), 7.06-6.99 (m, 4H) 6.63 (s, 1H), 4.02 (t, J = 8 Hz), 3.22 (s, 3H), 3.10 (t, J = 8 Hz). ¹³C (101 MHz, CDCl₃) δ 158.5, 156.1, 156.0, 155.2, 150.1, 140.1, 133.1, 133.0, 128.9, 128.5, 128.4, 128.3, 126.1, 115.7, 115.3, 106.1, 101.2, 52.6, 36.9, 33.8. IR (cm⁻¹) 3368 (br), 3084, 3064, 3026, 2928, 1603, 1545, 1513, 1453, 1233, 1172. HRMS (ESI) *m/z* calcd for C₂₆H₂₄N₂O₂ [M+H]⁺ 397.1916, found 397.1918.

36
37
38
39
40
41
42
43
44
45
46 **Associated Content**

47
48 **Supporting Information**

49
50 This material is available free of charge via the Internet at <http://pubs.acs.org>. Experimental details, characterization
51 data, x-ray crystallographic data, and spectra.

52
53
54 **Author Information**

55
56
57 **Corresponding Author**

1
2
3 louie@chem.utah.edu
4

5 **Notes**
6

7 The authors declare no competing financial interests.
8

9 **Acknowledgment**
10

11 We gratefully acknowledge the National Institute of Health (GM076125) for financial support. We also thank Dr. Jim
12 Muller and Dr. Atta R. Arif of the University of Utah for providing HRMS and for X-ray analysis of compound 4,
13 respectively.
14
15

16 **References**
17

- 18 (1) Varella, J. A.; Saá, C. *Chem. Rev.*, **2003**, *103*, 3787–3801.
19
20 (2) Kotha, S.; Brahmachary, E.; Lahiri, K. *Eur. J. Org. Chem.*, **2005**, 4741–4767.
21
22 (3) Chopade, P. R.; Louie, J. *Adv. Synth. Catal.*, **2006**, *348*, 2307–2327.
23
24 (4) Heller, B.; Hapke, M. *Chem. Soc. Rev.*, **2007**, *36*, 1085–1094.
25
26 (5) Shibata, T.; Tsuchikama, K. *Org. Biomol. Chem.* **2008**, *6*, 1317–1323.
27
28 (6) Varela, J. A.; Saá, C. *Synlett*, **2008**, *17*, 2571–2578.
29
30 (7) Galan, B. R.; Rovis, T. *Angew. Chem., Int. Ed.*, **2009**, *48*, 2830–2834.
31
32 (8) Ardizzoia, G. A.; Brenna, S.; LaMonica, G.; Maspero, A.; Masciochi, N. *J. Organomet. Chem.*, **2002**, *649*,
33 173-180.
34
35 (9) Gevorgyan, V.; Radhakrishnan, U; Takeda, A.; Rubina, M.; Rubin, M.; Yamamoto, Y. *J. Org. Chem.*, **2001**, *66*,
36 2835-2841.
37
38 (10) D'Souza, B. R.; Lane, T. K., Louie, J. *Org. Lett.* **2011**, *13*, 2936-2939.
39
40 (11) Lane, T. K.; D'Souza, B. R.; Louie, J. *J. Org. Chem.*, **2012**, *77*, 7555-7563.
41
42 (12) Wang, C.; Wang, D.; Xu, F.; Pan, B.; Wan, B. *J. Org. Chem.*, **2013**, *78*, 3065-3072.
43
44 (13) Stolley, R. M.; Maczka, M. T.; Louie, J. *Eur. J. Org. Chem.*, **2011**, 3815-3824.
45
46 (14) Varela, J. A.; Castedo, L.; Saá, C. *J. Org. Chem.*, **2003**, *68*, 8595-8598.
47
48 (15) Zhong, Y.; Spahn, N. A.; Stolley, R. M.; Minh, H. N.; Louie, J. *Synlett*, **2015**, *26*, 307-312.
49
50 (16) Lane, T. K.; Nguyen, M. H.; D'Souza, R. B.; Spahn, N. A.; Louie, J. *Chem. Commun.*, **2013**, *49*, 7735-7737.
51
52 (17) Inoue, T.; Itoh, Y.; Kazama, H.; Hashimoto, H. *Bull. Chem. Soc. Jpn.*, **1980**, *53*, 3329.
53
54 (18) Tsuda, T.; Sumiya, R.; Saegusa, T. *Synth. Commun.*, **1987**, *17*, 147.
55
56
57
58
59
60

- 1
2
3 (19) Tsuda, T.; Morikawa, S.; Sumiya, R.; Saegusa, T., *J. Org. Chem.*, **1988**, *14*, 3140-3145.
4
5 (20) Yamamoto, Y.; Kinpara, K.; Ogawa, R.; Nishiyama, H.; Itoh, K. *Chem. Eur. J.*, **2006**, *12*, 5618-5631.
6
7 (21) Xu, F.; Wang, C.; Li, X.; Wan, B. *ChemSusChem*, **2012**, *5*, 854-857.
8
9 (22) Tanaka, K.; Suzuki, N.; Nishida, G. *Eur. J. Org. Chem.*, **2006**, 3917-3922.
10
11 (23) Cioni, P.; Diversi, P.; Ingrosso, G.; Lucherini, A.; Ronca, P. *J. Mol. Catal.*, **1987**, *40*, 337-357.
12
13 (24) Pietro, D.; Ingrosso, G.; Lucherini, A.; Malquori, S. *J. Mol. Catal.*, **1987**, *40*, 267-280.
14
15 (25) Sugiyama, Y.; Okamoto, S. *Synthesis*, **2011**, *14*, 2247-2254.
16
17 (26) Boñaga, L. V. R.; Zhang, H.; Maryanoff, B. E. *Chem. Commun.*, **2004**, 2394-2395.
18
19 (27) Weding, N.; Jackstell, R.; Jiao, H.; Spannenberg, A.; Hapke, M. *Adv. Synth. Catal.* **2011**, *353*, 3423-3433.
20
21 (28) Theil, I.; Jiao, H.; Spannenberg, A.; Hapke, M. *Chem. Eur. J.* **2013**, *19*, 2548-2554.
22
23 (29) Auvinet, A-L.; Michelet, V.; Ratovelomanana-Vidal, V. *Synthesis*, **2013**, *45*, 2003-2008.
24
25 (30) Onodera, G.; Suto, M.; Takeuchi, R. *J. Org. Chem.*, **2012**, *77*, 908-920.
26
27 (31) Hashimoto, T.; Okabe, A.; Mizuno, T.; Izawa, M.; Takeuchi, R. *Tetrahedron*, **2014**, *70*, 8681-8689.
28
29 (32) Ardizzoia, G. A.; Brenna, S.; LaMonica, G.; Maspero, A.; Masciocchi, N. *J. Organomet. Chem.*, **2002**, *649*,
30
31 173-180.
32
33 (33) Ozerov, O. V.; Ladipo, F. T.; Patrick, B. O. *J. Am. Chem. Soc.*, **1999**, *121*, 7941-7942.
34
35 (34) Gevorgyan, V.; Radhakrishnan, U.; Takeda, A.; Rubina, M.; Rubin, M.; Yamamoto, Y. *J. Org. Chem.*, **2001**,
36
37 *66*, 2835-2941.
38
39 (35) Li, J.; Jiang, H.; Chen, M. *Org. Lett.*, **2001**, *66*, 3627-3629.
40
41 (36) Radhakrishnan, K. V.; Yoshikawa, E.; Yamamoto, Y. *Tetrahedron Lett.*, **1999**, *40*, 7533-7535.
42
43 (37) Dieck, H.; Diercks, R. *Angew. Chem., Int. Ed.*, **1983**, *22*, 1138-1146.
44
45 (38) Breschi, C.; Piparo, L.; Pertici, P.; Caporusso, A. M.; Vitulli, G. *J. Organomet. Chem.*, **2000**, *607*, 57-63.
46
47 (39) Richard, V.; Ipouck, M.; Mérel, D. S.; Gaillard, S.; Whitby, R. J.; Witulski, B.; Renaud, J-L. *Chem. Commun.*
48
49 **2014**, *50*, 593-595.
50
51 (40) Wang, C.; Li, X.; Wu, F.; Wan, B. *Angew. Chem. Int. Ed.* **2011**, *50*, 7162-7166.
52
53 (41) Nakajima, K.; Liang, W.; Nishibayashi, Y. *Org. Lett.* **2016**, *18*, 5006-5009.
54
55 (42) Nakajima, K.; Takata, S.; Sakata, K.; Nishibayashi, Y. *Angew. Chem. Int. Ed.* **2015**, *54*, 7597-7601.
56
57 (43) Zhang, J.; Zhang, Q.; Xia, B.; Wu, J.; Wang, X-N.; Chang, J. *Org. Lett.*, **2016**, *18*, 3390-3393.
58
59
60

(44) Wang, Y.; Song, L.-J.; Zhang, X.; Sun, J. *Angew. Chem. Int. Ed.* **2016**, *55*, 9704-9708.

(45) Saino, N.; Kogure, D.; Kase, K.; Okamoto, S. *J. Organomet. Chem.* **2006**, *691*, 3129-3136.

(46) Liu, Y.; Yan, X.; Yang, N.; Xi, C. *Catal. Commun.* **2011**, *12*, 489-492.

(47) Russell, S. K.; Milsmann, C.; Lobkovsky, E.; Weyhermüller, T.; Chirik, P. *Inorg. Chem.*, **2011**, *50*, 3159-3169.

(48) Lefèvre, G.; Jutand, A. *Chem. Eur. J.*, **2014**, *20*, 4796-4805.

(49) Huang, Y.; Moret, M.-E.; Gebbink, R. J. M. K. *Eur. J. Org. Chem.*, **2014**, 3788-3793.

(50) Arabczyk, W.; Moszyński, D.; Narkiewicz, U.; Pelka, R.; Podsiadly, M. *Catal. Today*, **2007**, *124*, 43-48.

(51) Henke, B. R.; Drewry, D. H.; Jones, S. A.; Stewart, E. L.; Weaver, S. L.; Wiethe, R. W. *Bioorg. Med. Chem. Lett.*, **2001**, *11*, 1939-1942.

(52) Katritzky, A. R.; Belyakov, S. A.; Sorochinsky, A. E.; Henderson, S. A.; Chen, J. *J. Org. Chem.* **1997**, *62*, 6210-6214.

TOC GRAPHIC:

